A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of WJ01075 Tablets in Oral Dose Escalation and Expansion in Patients With Advanced Solid Tumors
Latest Information Update: 04 Sep 2023
At a glance
- Drugs WJ-01075 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Suzhou Junjing BioSciences
- 29 Aug 2023 Status changed from recruiting to discontinued.
- 24 Nov 2022 Status changed from not yet recruiting to recruiting.
- 29 Jul 2022 New trial record